Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact
Eli Lilly is further expanding its RNA medicine strategy by tapping up South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss.
Eli Lilly is further expanding its RNA medicine strategy by tapping up South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss.
